EMF / PV Cancer Research Results

RF, EMF: Click to Expand ⟱
Features:
radiofrequency (RF) electromagnetic fields (EMF)

-example 27.12 MHz https://www.therabionic.com/ TheraBionic P1

Radiofrequency electromagnetic fields — non-ionizing electromagnetic fields within the radiofrequency spectrum that can be delivered using highly divergent exposure configurations, including low-power amplitude-modulated systemic fields, transcranial fields, localized dielectric heating, thermal ablation, and nanoparticle-assisted RF treatment. RF electromagnetic field therapy is a physical medical-device modality rather than a drug; standard abbreviations include RF, RF-EMF, AM RF-EMF for amplitude-modulated RF fields, and TEMT for transcranial electromagnetic treatment. For this database entry, the most relevant anticancer implementation is the non-thermal TheraBionic platform, which uses a 27.12 MHz carrier amplitude-modulated at tumor-specific low frequencies and delivered through an intraoral antenna. This modality must not be conflated with thermal radiofrequency ablation, RF hyperthermia, tumor-treating fields, microwave ablation, or ordinary environmental RF exposure because their field strengths, frequencies, tissue interactions, and clinical evidence differ substantially.

Primary mechanisms (ranked):

  1. Tumor-specific modulation-frequency sensing followed by selective disruption of cancer-cell proliferation and mitosis.
  2. CaV3.2 T-type calcium-channel engagement with altered Ca²⁺ influx and downstream IP3, DAG, and calcium-dependent signaling.
  3. Mitotic-spindle and chromosome-segregation disruption, producing mitotic arrest or abnormal mitotic progression.
  4. Altered PLK1-associated mitotic signaling and suppression of clonogenic tumor-cell growth.
  5. Context-dependent differentiation, apoptosis, or non-apoptotic loss of viability after prolonged repeated exposure.
  6. ROS modulation is secondary and inconsistent across RF exposure systems; it is not a sufficiently established core mechanism for tumor-specific AM RF-EMF therapy.

Bioavailability / PK relevance: Conventional pharmacokinetics do not apply. Biological exposure depends on carrier frequency, modulation frequencies, electric-field strength, specific absorption rate, antenna coupling, tissue conductivity, treatment duration, duty cycle, body geometry, and field distribution. The TheraBionic P1 is administered for one hour three times daily through an antenna placed in the mouth, producing low-level systemic RF exposure. Clinical translation cannot be inferred from frequency alone.

In-vitro vs systemic exposure relevance: RF-EMF effects are not concentration-driven. In-vitro findings are relevant only when carrier frequency, modulation pattern, field amplitude, dosimetry, temperature, exposure duration, antenna geometry, and electromagnetic compatibility are reproduced. Results from high-power or thermally confounded systems cannot be extrapolated to low-power non-thermal tumor-specific AM RF-EMF exposure.

Clinical evidence status: FDA humanitarian-device authorization with limited clinical evidence. TheraBionic P1 received US Humanitarian Device Exemption approval for adults with advanced hepatocellular carcinoma that has failed first- and second-line systemic therapy. The authorization is based on probable benefit rather than the conventional reasonable-assurance-of-effectiveness standard and requires post-approval evaluation. Evidence for other cancers remains preclinical, compassionate-use, case-series, or early clinical research. This broad RF entry should therefore be classified as clinically deployed for a narrow HCC indication, but investigational for most other systemic anticancer uses.


RF-EMF Anticancer Mechanisms

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Tumor-specific frequency response Proliferation ↓ Proliferation ↔ G Selective growth inhibition Reported for defined amplitude-modulation frequencies superimposed on a 27.12 MHz carrier; frequency specificity remains incompletely characterized and is device-dependent.
2 CaV3.2 calcium-channel signaling Ca²⁺ signaling altered Uncertain P R Signal transduction and differentiation CaV3.2 involvement has been demonstrated principally in hepatocellular carcinoma models and should not be generalized to all cancers or RF systems.
3 IP3 and DAG signaling IP3 ↑
DAG ↑		 Uncertain P R Calcium-dependent antiproliferative signaling Downstream response associated with tumor-specific AM RF-EMF exposure and CaV3.2-dependent signaling.
4 Mitotic spindle integrity Spindle organization ↓
Chromosome segregation abnormal		 Limited change reported R G Mitotic disruption Observed in HCC and more recently in glioblastoma models; biological relevance depends on tumor-specific modulation frequencies.
5 PLK1-associated mitotic signaling PLK1 pathway altered Uncertain R G Mitotic arrest and reduced clonogenicity Direction can vary by sampling time because pathway activation may represent mitotic stress rather than productive proliferation.
6 Cell differentiation Differentiation ↑ ↔ G Reduced malignant phenotype Strongest evidence is in HCC models and is linked experimentally to CaV3.2 signaling.
7 Cell-cycle progression Cell-cycle progression ↓ Limited effect reported G Growth arrest Repeated exposure is generally required; effects are not equivalent to acute RF heating.
8 Apoptosis and cell viability Apoptosis ↑
Viability ↓		 Viability ↔ G Tumor-cell loss Magnitude and death phenotype are model-dependent; growth arrest may predominate over rapid cytotoxicity.
9 Oxidative stress ROS ↑ or ↔ (context-dependent) ROS ↑, ↓, or ↔ (exposure-dependent) P R G Secondary stress response Results across the RF literature are heterogeneous and often depend on power, temperature, cell type, exposure chamber, and dosimetry. ROS should not be presented as a universal RF anticancer mechanism.
10 Chemosensitization Drug response ↑ (model-dependent) Uncertain G Potential adjunct activity Combination evidence is preliminary and cannot yet support a general clinical chemosensitizer classification.
11 Clinical Translation Constraint Response heterogeneous Low reported toxicity for the authorized device G Restricted clinical generalizability Effects depend on device-specific modulation frequencies, coupling, dosimetry, treatment adherence, tumor identity, and field geometry. FDA authorization applies only to advanced HCC after failure of first- and second-line therapy and was based on limited probable-benefit evidence.

P: 0–30 min    R: 30 min–3 hr    G: >3 hr



Radiofrequency electromagnetic fields in Alzheimer’s disease — transcranial RF-EMF systems such as transcranial electromagnetic treatment deliver repeated non-ionizing fields through multiple emitters positioned around the head. Experimental systems generally use RF exposure intended to remain below tissue-heating thresholds. Proposed effects include interference with amyloid-β aggregation, enhancement of mitochondrial function, altered neuronal bioenergetics, and possible changes in cerebral perfusion. This application is distinct from both the TheraBionic cancer device and transcranial magnetic stimulation.

Primary mechanisms (ranked):

  1. Destabilization or reduced accumulation of soluble and aggregated amyloid-β species.
  2. Improved mitochondrial electron-transport function, membrane potential, and ATP production.
  3. Possible enhancement of cerebral blood flow and neuronal metabolic activity.
  4. Secondary modulation of oxidative stress and inflammatory signaling.

Bioavailability / PK relevance: Pharmacokinetics do not apply. Relevant variables include carrier frequency, specific absorption rate, emitter arrangement, skull and tissue conductivity, treatment duration, and intracranial field uniformity.

In-vitro vs systemic exposure relevance: RF effects are not concentration-driven. Cell-culture, mouse, and human results cannot be compared without matched dosimetry and thermal controls. Amyloid effects reported under one RF protocol do not establish a general effect of environmental RF exposure.

Clinical evidence status: Small human feasibility studies only. Early open-label trials reported acceptable short-term tolerability and exploratory cognitive or biomarker signals, but the samples were very small and lacked adequate blinded randomized controls. Extension studies have been registered, but RF-EMF is not an approved Alzheimer’s disease treatment and efficacy remains unproven.


RF-EMF Mechanisms in Alzheimer’s Disease

Rank Pathway / Axis Modulation TSF Primary Effect Notes / Interpretation
1 Amyloid-β aggregation and clearance Aβ oligomers ↓
Aβ deposition ↓		 G Reduced amyloid burden Supported mainly by cell-culture and transgenic-mouse studies; human biomarker confirmation remains limited.
2 Mitochondrial electron transport ETC function ↑
Membrane potential ↑		 R G Improved neuronal bioenergetics Preclinical evidence suggests mitochondrial effects may contribute to cognitive changes.
3 ATP production ATP ↑ R G Improved cellular energy availability Evidence is predominantly preclinical and protocol-specific.
4 Cerebral perfusion Blood flow ↑ (region-dependent) R G Improved metabolic support Regional perfusion changes have been reported, but clinical importance is uncertain.
5 Oxidative stress ROS ↓ or ↑ (context-dependent) P R G Secondary redox modulation Beneficial and adverse redox effects have both been described under different RF protocols; exposure parameters are decisive.
6 Cognition and memory Cognition ↑ (preliminary) G Possible functional improvement Signals derive from animal studies and very small uncontrolled human studies; efficacy is not established.
7 Clinical Translation Constraint Evidence limited G Investigational status Small cohorts, open-label designs, heterogeneous RF protocols, incomplete sham control, uncertain durability, and absence of regulatory approval prevent clinical efficacy conclusions.

P: 0–30 min    R: 30 min–3 hr    G: >3 hr
PV, Prostate Volume: Click to Expand ⟱
Source:
Type:

Prostate Volume
Scientific Papers found: Click to Expand⟱
6935- RF,    Effects of pulsed electromagnetic fields on benign prostate hyperplasia
- Human, BPH, NA
*Dose↝, *PV↓, *UFR↑, *UR↓, *QoL↑, *Dose↝, *Dose↝, *Dose↝, *Dose↝,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Total Targets: 0

Pathway results for Effect on Normal Cells:


NA, unassigned(tgid=0) ⓘ

PV↓, 1,   UFR↑, 1,   UR↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

Dose↝, 5,  

Functional Outcomes(tgid=23) ⓘ

QoL↑, 1,  
Total Targets: 5

Scientific Paper Hit Count for: PV, Prostate Volume
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:329  Target#:1540  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page